- BIOKINESIS absorption by DIACCURATE occurred early December 2020
- Dr. Dominique BRIDON leads the brand new entity
- DIACCURATE is now creating 3 applications in most cancers and immunotherapy
- DIACCURATE will likely be initiating a primary scientific trial by early 2022
Paris, France, January 12, 2021
By buying BIOKINESIS, a French biotech that develops the very first anticancer compound concentrating on the Golgi equipment, DIACCURATE comforts its “sole-in-class” therapeutic technique in oncology and immunotherapy. The corporate is creating a brand new era of drug candidates which depends on novel mechanisms of motion and untapped mobile and subcellular compartments. Preliminary knowledge already recommend that this extremely revolutionary method might assist to enhance resitance to most cancers development and prolong the advantages of immunotherapy to extra indications and sufferers.
“I’m delighted to affix DIACCURATE the previous 12 months and I’m extraordinarily impressed by the scientific rationale and the excessive stage of experience of the corporate. This acquisition provides us the chance to guide an thrilling “sole-in-class” method in a brand new entity with a world outlook and a really bold growth technique. Thus, DIACCURATE ought to quickly prolong its portfolio by in licensing a drug-candidate with excessive therapeutic potential in oncology” defined Dr. Dominique BRIDON, CEO of DIACCURATE.
“I’m satisfied the synergies ensuing from this merger will in the end assist to take up the primary present problem of oncology and immunotherapy: broaden the efficacy of checkpoints inhibitors and therapeutics vaccines by restoring a functionnal immune system. That’s the reason TRUFFLE CAPITAL, main investor of the 2 firms has been driver in creating a brand new entity with a powerful and differentiated worth proposition.” acknowledged Dr. Philippe POULETTY, Co-founder and Chairman of DIACCURATE, Co-founder and CEO of TRUFFLE CAPITAL.
“The BIOKINESIS acquisition will give the means to speed up the event of the KIF20A inhibitor DIACC2010, the very first Golgi-targeted drug candidate. This attitude is thrilling given the spectacular preclinical knowledge proven in Acute Myeloid Leukemia and Lymphoma. I’m very pleased to affix the DIACCURATE crew as VP Operations” stated Cécile BOUGERET, former CEO & CSO of BIOKINESIS, now VP Operations at DIACCURATE.
Dr. Philippe POULETTY, Chairman
Co-founder and CEO of TRUFFLE CAPITAL, Philippe is a pioneer in biotechnology and medical gadgets. He based SANGSTAT in 1988, an organization specialised in organ transplant remedy, listed on the NASDAQ, then CONJUCHEM in 1993, a biotech firm specialised in therapeutic peptides, listed on the TORONTO STOCK EXCHANGE. He based/co-founded amongst others: CARMAT, DEINOVE, ABIVAX, PHARNEXT, VEXIM; TRUFFLE CAPITAL portfolio firms.
Philippe graduated as a Physician of Drugs from the PARIS VI UNIVERSITY, holds Grasp’s levels in Immunology and Virology from INSTITUT PASTEUR and accomplished his Put up-Doctoral Analysis at STANFORD UNIVERSITY. He’s the previous Chairman and Honorary Chairman of the French biotech business affiliation FRANCE BIOTECH and former Vice-Chairman of the European Affiliation for the biotechnology business EUROPABIO.
Creator of 29 patents, Philippe is the 1999 laureate of the American Liver Basis, member of the STANFORD’s prestigious Invention Corridor of Fame and Chevalier of the Legion of Honor.
Dr. Dominique BRIDON, Chief Government Officer
Dominique brings greater than 30 years of pre-clinical and scientific growth expertise with management positions throughout North America, most lately, as CTO for EPIVAX ONCOLOGY creating customized most cancers peptide vaccines within the bladder most cancers setting. Concurrently to his function at EPIVAX, he acted as Head of Therapeutics for CONCARLO, a Brooklyn-based firm creating pan CDK inhibitors for the remedy of breast most cancers.
Beforehand, Dominique was CEO at BIODESY, a start-up financed by 5AM, ROCHE and PFIZER VENTURES specialised within the detection of protein conformational modifications. Previous to that function, he led the event of novel transporter-mediated oncology and CNS medication at OPTIVIA. He additionally held varied management positions at IPSEN, CONJUCHEM, REDCELL and ABBOTT, served as a Director for ENOBIA (acquired by ALEXION) and NEURONAX and was a member of the Scientific Advisory Board of SYNTAXIN (acquired by IPSEN) and BIOSORTIA.
Dominique holds a Grasp of Science in Chemical Engineering and Polymer Sciences from ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE and a PhD in Natural Chemistry from the UNIVERSITY OF PARIS XI, with the Nobel Laureate Sir Derek H. R. BARTON as Analysis Advisor. He accomplished his Put up-Doctoral Analysis on the UNIVERSITY OF BERKELEY.
José DA GLORIA, Chief Monetary Officer
Earlier than becoming a member of DIACCURATE, José was EVP Chief Monetary Officer at VEXIM, a French publicly listed firm (Euronext development) that developed and marketed an revolutionary medical machine to deal with vertebral compression fractures (acquired by STRYKER in 2017). He additionally participated within the launch of CLOUDWATT, a French start-up of cloud computing, now a part of ORANGE Enterprise Companies.
Beforehand José was Monetary controller of a $250 million Worldwide division at EV3, a US Medtech specialised in vascular implants (acquired by COVIDIEN, now MEDTRONICS).
He participated within the enterprise growth within the rising international locations (Latin America and Asia) in addition to the monetary, logistic and financial integration of the EV3 entities inside COVIDIEN. Additional to this integration, he joined COVIDIEN because the EMEA FP&A Director. José started his profession within the IT business as FP&A analyst and took varied finance and management roles inside DELL INC.
José is a college graduate of UNIVERSITY PARIS-SACLAY with a Grasp’s diploma in Financial system and Finance.
Dr. Cécile BOUGERET, VP Operations
Previous to becoming a member of DIACCURATE, Cécile held a number of scientific administration positions at DIATOS, CYTOMICS PHARMACEUTICALS and BIOKINESIS, 3 biotechnology firms specialised in oncology. She brings 20 years of expertise within the subject of oncology drug analysis and growth.
Cécile holds a PhD in biology from the PARIS VII UNIVERSITY. She accomplished her Put up-Doctoral Analysis at ROCKEFELLER UNIVERSITY in New York and at HARVARD MEDICAL SCHOOL in Boston.
Cécile is member of the AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR).
Dr. Jérôme TIOLLIER, VP Growth
Jérôme has been working since 35 years in pharmaceutical R&D with expertise in senior management positions in a number of biopharmaceutical firms.
Previous to becoming a member of DIACCURATE, Jérôme was EVP Chief Growth Officer at INNATE PHARMA the place he constructed the event crew group and managed a number of areas of drug growth, together with CMC toxicology, PK, non scientific POC, translational analysis and scientific & regulatory operations as much as early scientific phases of the totally different “first-in-class” immunotherapy antibodies of the corporate portfolio.
Beforehand, he was Preclinical Director then European R&D Director at PASTEUR-MERIEUX Transplant enterprise unit (acquired by SANGSTAT, now a part of SANOFI GENZYME). Jérôme can be co-founder and Chairman of OUR FUTURE UNIVERSE (OFU), the primary meta media specialised in biomedical analysis and innovation. Jérôme is graduated from CLAUDE BERNARD UNIVERSITY-LYON as PhD.
Prof. Jacques THÈZE
Jacques is a world main authority within the fields of CD4 biology and HIV an infection. Creator of greater than 250 scientific and medical publications, he has found the blood molecular driver of CD4 immunodeficiency and co-founded DIACCURATE.
Former Professor and Head of the Human Immunology Division on the PASTEUR INSTITUTE in Paris and Hospital Practition er at APHM, Jacques was President of the INSERM immunology fee and Basic Director of the Pasteur Institute in Lyon. He was additionally scientific adviser for the WORLD HEALTH ORGANIZATION (new vaccine program) and SANOFI (cytokines and immunotherapy program).
Graduated from the FACULTY OF MEDICINE in Bordeaux, Jacques was educated as immunologist and virologist on the PASTEUR INSTITUTE. He holds a PhD within the molecular biology division of François JACOB and Jacques MONOD, NOBEL PRIZE in Drugs 1965 and accomplished his Put up-Doctoral Analysis on the HARVARD MEDICAL SCHOOL within the Analysis Division of Baruj BENACERRAF, NOBEL PRIZE in Drugs 1981. Jacques is corresponding member of the FRENCH NATIONAL ACADEMY OF MEDICINE.
Spin-off from the Pasteur Institute in Paris, DIACCURATE is a late preclinical stage biotechnology firm which develops “sole-in-class” therapeutics in oncology and immunotherapy. DIACCURATE is conducting 3 proprietary growth applications of highy revolutionary drug-candidates: the KIF20A inhibitor DIACC2010 disrupts intracellular trafficking to cut back development of most cancers cells whereas the anti-PLA2G1B antibody DIACC1010 restores CD4 T cells altered features in most cancers and HIV. In the middle of 2022, the corporate will enter its first scientific trial.
Led by Dr. Dominique BRIDON, DIACCURATE was co-founded by Prof. Jacques THÈZE, a world main authority within the subject of CD4 biology and Dr Philippe POULETTY, biotech and medtech pionner, co-founder and CEO of TRUFFLE CAPITAL.
About TRUFFLE CAPITAL
Created in 2001, TRUFFLE CAPITAL is an unbiased European Enterprise Capital firm, specialising in life sciences (MedTech and Biotech) and in breakthrough IT applied sciences (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to assist the creation and growth of younger innovating firms, able to changing into tomorrow’s leaders.
Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 firms within the digital expertise and life sciences sectors. In 2019, TRUFFLE CAPITAL introduced having raised nearly €400 million in new institutional funds, together with €250 million for brand spanking new BioMedTech investments.